Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00697268 · ClinicalTrials.gov registry record
p11 Protein Levels in Patients With Major Depressive Disorder Treated With Citalopram
A clinical trial of Depression, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- 38
- Enrollment target
- 1
- Study location
NCT00697268: Completed study of Depression, sponsored by National Institute of Mental Health (NIMH).
NCT00697268 is a study of Depression that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 38 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00697268, a study of Depression, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare levels of p11 protein in people with and without major depressive disorder (MDD) and examine if p11 levels in patients are affected by treatment with citalopram (Celexa). Healthy normal volunteers and patients with chronic or recurrent major depression between 18 and 65 years of age may be eligible for this study. Participants undergo the following tests and procedures: Healthy Volunteers * Psychiatric interview and medical examination, questions about family history * Blood draw Patients with MDD Phase 1 - Evaluation and Discontinuation of Medications * Physical examination, electrocardiogram, blood tests * Gradual antidepressant medication withdrawal, followed by 2- to 6-week drug-free period. If needed, medicines for anxiety and difficulty sleeping may be prescribed. Phase 2 Citalopram Treatment * Start daily citalopram treatment * Evaluations at the start of phase 2 and every week for 8 weeks with following procedures: * Symptoms ratings interview and questionnaires * Review of side effects and new medications * Blood pressure and pulse measurements * Blood and urine tests At the end of the study, plans are developed for long-term treatment and transfer of care to the patient s own physician. ...
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2008-06-03 |
| Est. Completion | 2016-07-28 |
What the finished NCT00697268 record still lists
NCT00697268 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 0 interventions.
NCT00697268 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00697268 about?
NCT00697268 is a clinical study titled "p11 Protein Levels in Patients With Major Depressive Disorder Treated With Citalopram". This study will compare levels of p11 protein in people with and without major depressive disorder (MDD) and examine if p11 levels in patients are affected by treatment with citalopram (Celexa). Healthy normal volunteers and patients with chronic or recurrent major depression between 18 and 65 year...
What is the current status of trial NCT00697268?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2008-06-03. Estimated completion is 2016-07-28.
What conditions does trial NCT00697268 study?
This clinical trial studies the following conditions: Depression.
Who is sponsoring clinical trial NCT00697268?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00697268 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00697268's enrollment target sits among peer trials
38 531st of 679 higher than 146 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
Depression and Driving
RECRUITING
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy